Addex Therapeutics grants officer 3.77M stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Addex Therapeutics Ltd. (ADXN) granted its principal accounting officer, Lenaic Nathanael Teyssedou, 3,771,415 stock options on November 11, 2026. The options have an exercise price of $0.0260 per share, reported in U.S. dollars after conversion from CHF at $1.1995 per CHF 1.00. They vest in equal monthly installments over four years beginning at the exercisable date; each option gives the right to purchase one ADXN share. The reported total following the grant was 4,374,323.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock-option (Right to Buy) F2, F1 | 3,771,415 | $0.00 | $0.00 |
Footnotes (2)
- F1. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
- F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.
Key Figures
Key Terms
exercise price financial
vest on equal monthly installments technical
exercisable date technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options did ADXN's principal accounting officer receive?
AI-generated analysis. How Rhea-AI works. Not financial advice.